FIELD: chemistry.
SUBSTANCE: invention relates to a compound of formula I and/or pharmaceutically acceptable salts and/or stereoisomers thereof, which are c-KIT kinase inhibitors. In formula IR1 means H, Hal, CF3, NO2, A, [C(R3)2]nN(R3)2, [C(R3)2]nHet1, OR3, O[C(R3)2]nN(R3)2, O[C(R3)2]nS(O)mR3, O[C(R3)2]nHet1, O[C(R3)2]nN(R3)Het1, O[C(R3)2]nPh or O[C(R3)2]nCyc, R2 denotes H or CH3, R3 denotes H or A, V denotes H or Hal, X denotes O or N(R3), Y denotes phenylene, pyridine diyl or thiophenediyl, each of which is not substituted or mono-, di- or tri-substituted by Hal and/or A, Z denotes CON(R3)2, phenyl, Het4 or -O-A, Het1 denotes 4–7-membered monocyclic aromatic or saturated heterocycle containing from 1 to 3 atoms of N, O and/or S, which can be unsubstituted or mono-, di- or trisubstituted by A, Hal, CN, OR3, [C(R3)2]nN(R3)2, [C(R3)2]nSO2R3, Het2, oxetanyl and/or = O and in which the N atom can be oxidised, or denotes 6–10-membered bicyclic or spirocyclic aromatic, unsaturated or saturated heterocycle containing from 1 to 4 N, O and/or S atoms, which can be unsubstituted or mono- or disubstituted by A and/or = O, Het2 denotes 5–6-membered monocyclic aromatic heterocycle, containing from 1 to 3 atoms of N, O and/or S, which can be unsubstituted or mono- or disubstituted by A, Het3 denotes 4–7-membered monocyclic saturated heterocycle containing 1 to 2 N and/or O atoms, Het 4 denotes 4–7-membered monocyclic aromatic, unsaturated or saturated heterocycle containing 1 to 4 N atoms and/or O, which can be unsubstituted or mono-, di- or trisubstituted by A, Hal, OR3, [C(R3)2]nHet3, -N(R3)2 and/or = O, or denotes 6–10-membered bicyclic aromatic, unsaturated or saturated heterocycle containing from 1 to 2 N and/or O atoms, A denotes a straight or branched alkyl containing 1–10 C atoms, in which 1–3 CH- and/or CH2-groups not located nearby can be replaced with O atoms and in which 1–7 H atoms can be replaced with R5, or denotes (CH2)nCyc, Cyc denotes a cyclic alkyl containing 3–7 C atoms, R5 denotes F, Cl, CN or OH, m denotes 0, 1 or 2, n denotes 0, 1, 2, 3 or 4. Invention also relates to methods of producing said compound, a medicinal agent based thereon and intermediate compounds.
EFFECT: inventions can be used for treating a malignant neoplasm representing a gastrointestinal stromal tumour.
17 cl, 4 tbl, 32 ex
| Title | Year | Author | Number |
|---|---|---|---|
| QUINOLINE-2 DERIVATIVES AS C-KIT KINASE INHIBITORS | 2016 |
|
RU2754858C2 |
| TLR7/8 ANTAGONISTS AND THEIR APPLICATION | 2017 |
|
RU2758686C2 |
| OXOQUINAZOLINYL-BUTANAMIDE DERIVATIVES | 2014 |
|
RU2669393C2 |
| FURO[3,2-B]- AND THIENO[3,2-B]PYRIDINE DERIVATIVES AS TBK1 AND IKKε INHIBITORS | 2013 |
|
RU2622034C2 |
| TRIAZOLO-PYRIMIDINE COMPOUNDS AND THEIR USE | 2019 |
|
RU2802866C2 |
| 3-AMINOCYCLOPENTANCARBOXAMIDE DERIVATIVES | 2013 |
|
RU2641913C2 |
| PYRIDAZINONE-AMIDE DERIVATIVES | 2014 |
|
RU2666899C2 |
| CALPAIN MODULATORS AND THEIR THERAPEUTIC USE | 2017 |
|
RU2773288C2 |
| HETEROCYCLIC COMPOUND AS PROTEIN KINASE INHIBITOR | 2018 |
|
RU2783723C2 |
| MACROCYCLIC PYRIDAZINONE DERIVATIVES | 2014 |
|
RU2660435C2 |
